TRDA (Entrada Therapeutics) Insider Ownership: 3.15 % (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRDA Entrada Therapeutics Inc TRDA
26 GF Score
Price $7.00
GF Value $0.39
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Entrada Therapeutics Insider Ownership?

Entrada Therapeutics TRDA -8.02% 26 Insider Ownership is 3.15 % as of Aug. 26, 2026. GuruFocus rates TRDA with a GF Score™ of 26/100 and a GF Value™ of $0.39 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Entrada Therapeutics's insider ownership is 3.15%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Entrada Therapeutics's Institutional Ownership is 70.30%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Entrada Therapeutics's Float Percentage Of Total Shares Outstanding is 64.44%.

Entrada Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Entrada Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entrada Therapeutics Insider Ownership Chart

Entrada Therapeutics Historical Data

The historical data trend for Entrada Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 2.87 2.87 2.83 2.83 2.79 2.79 2.79 3.15 3.15 3.15
TRDA
26GF Score
Entrada Therapeutics Inc TRDA
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entrada Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 3.15 % mean?
Entrada Therapeutics (TRDA) has a Insider Ownership of 3.15 % as of Aug. 26, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Entrada Therapeutics and its competitors.
Is Entrada Therapeutics' Insider Ownership too high?
Entrada Therapeutics' current Insider Ownership is 3.15 %. Overall, Entrada Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Insider Ownership compare to ACIU and TARA?
Entrada Therapeutics' Insider Ownership of 3.15 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Entrada Therapeutics and its competitors. Entrada Therapeutics's current Insider Ownership is 3.15 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.39, compared to a current price of $7.00 — trading 1694.9% above its estimated fair value. The current Insider Ownership is 3.15 %. Entrada Therapeutics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Insider Ownership is 3.15 % as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.00 is trading 1694.9% above its estimated GF Value™ of $0.39. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Insider Ownership: 3.15 %
  • GF Value™: $0.39 vs. price of $7.00 (1694.9% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
26GF Score

Get the complete analysis for TRDA

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$0.39
GF Value